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Background: CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the
antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in
patients with advanced castration-resistant prostate-cancer.
Methods: 44 Patients received up to 5 intra-dermal vaccinations. Three dose levels of total mRNA were tested in
Phase I in cohorts of 3–6 patients to determine a recommended dose. In phase II, 32 additional patients were
treated at the recommended dose. The primary endpoint was safety and tolerability, the secondary endpoint was
induction of antigen specific immune responses monitored at baseline and at weeks 5, 9 and 17.
Results: The most frequent adverse events were grade 1/2 injection site erythema, injection site reactions, fatigue,
pyrexia, chills and influenza-like illness. Possibly treatment related urinary retention occurred in 3 patients. The
recommended dose was 1280 μg. A total of 26/33 evaluable patients treated at 1280 μg developed an immune
response, directed against multiple antigens in 15 out of 33 patients. One patient showed a confirmed PSA
response. In the subgroup of 36 metastatic patients, the Kaplan-Meier estimate of median overall survival was
31.4 months [95 % CI: 21.2; n.a].
Conclusions: The self-adjuvanted RNActive® vaccine CV9103 was well tolerated and immunogenic.
The technology is a versatile, fast and cost-effective platform allowing for creation of vaccines. The follow-up
vaccine CV9104 including the additional antigens prostatic acid phosphatase (PAP) and Muc1 is currently being
tested in a randomized phase IIb trial to assess the clinical benefit induced by this new vaccination approach.
Trial registration: EU Clinical Trials Register: EudraCT number 2008-003967-37, registered 27 Jan 2009.Background
Prostate cancer (PCa) remains the second leading cause of
cancer death in men, accounting for 29,720 estimated can-
cer deaths in the US in 2013 [1]. While early diagnosis of
PCa is associated with a 5-year disease-specific survival rate
(SR) of 100 %, only 27.8 % 5-year SR is reported for patients
with metastatic disease (SEER Stat Fact Sheet on prostate
cancer, http://seer.cancer.gov). Advanced PCa is usually* Correspondence: birgit.scheel@curevac.com
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(http://creativecommons.org/publicdomain/zerotreated with hormone ablation therapy leading to tumor
shrinkage [2]. However, tumors may relapse after a period
of time ranging from a few months to several years at
which time they progress into castration-resistant prostate
cancer (CRPC). Treatment options for patients with meta-
static CRPC include second generation anti-hormonal
agents such as abiraterone or enzalutamide or palliative
chemotherapy with docetaxel or cabazitaxel, which increase
survival by 2–4 months [3]. In the past years, immunother-
apeutic approaches have become more and more relevant.
The cell-based therapeutic vaccine Sipuleucel T targeting
the antigen PAP has been approved by the US Food andticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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Medicines Agency for the treatment of asymptomatic –
minimally symptomatic metastatic CRPC based on a
median prolongation in overall survival by 4.1 months
compared to placebo controls [4]. Another prostate can-
cer vaccine against PSA, Prostvac-VF, has shown an im-
provement in median overall survival by 8.5 months in a
double blind placebo controlled phase II trial [5].
Vaccination with messenger RNA (mRNA) encoding
full-length tumor antigens is a novel option for immuno-
therapy. Early experiments showed that intradermal ad-
ministration of mRNA led to protein expression and
induction of humoral and cellular antigen-specific immune
responses in mice [6–9]. In a phase I/II trial in patients
with metastatic melanoma, direct intra-dermal injection of
mRNA coding for relevant tumor-associated antigens was
well tolerated and influenced the frequency of vaccine-
antigen directed CD4 and CD8 T cells as well as regulatory
T cells (T Regs). One stage IV patient showed a complete
response of lung metastases, and after a relapse that was
surgically treated remains tumor free until today [10].
RNActive® vaccines are novel, mRNA-based vaccines
containing both free and protamine-complexed mRNA.
They support optimal expression of the encoded antigen as
well as innate immune stimulation with a built-in adjuvan-
ticity that is at least partly mediated via Toll-like receptor 7
activation [11, 12]. In mice, immunization with these self-
adjuvanted vaccines leads to a boostable and balanced
humoral as well as T cell-mediated antigen-specific immun-
ity, which is long lived as shown by presence of antigen-
specific memory T cells [13, 14].
CV9103 is such a self-adjuvanted mRNA vaccine target-
ing 4 antigens: prostate-specific antigen (PSA), prostate-
specific membrane antigen (PSMA), prostate stem cell
antigen (PSCA), and six-transmembrane epithelial antigen
of the prostate 1 (STEAP1). In healthy men, these antigens
are frequently and almost exclusively expressed in the
prostate [15–18], and overexpressed in prostate cancer;
with the exception of PSMA which is also overexpressed
in the tumor-neovasculature of other cancers [15, 19]. After
radical prostatectomy or radiation, these antigens are mainly
found on residual prostate cancer cells [20–25]. In addition,
all four antigens were shown to be immunogenic in
humans, where they induce T and B cell responses [26–28].
CV9103 encodes full-length antigens and thus has the
advantage to induce an immune response against all epi-
topes contained in the target protein without HLA-
restrictions. This, and the inclusion of multiple antigens,
was developed to reduce the risk of tumor immune escape
due to loss of expression of individual antigens [28], to in-
crease the clinical efficacy by inducing a broader immune
response and to provide immune responses against anti-
gens present in the individual tumor in a higher number of
patients.Here we report the results of a phase I/IIa study that
evaluated the safety and tolerability of CV9103 following
intradermal administration in patients with advanced
CRPC. The induction of antigen-specific immune re-
sponses is also reported.
Results
Patient characteristics
Between January and November 2009, 50 patients with
advanced CRPC were screened at 12 centers in Germany
and Italy. 44 patients were eligible, started treatment
with CV9103 and were included in the safety population.
Of these, 12 patients were enrolled in the phase I part of
the study and 32 patients in the phase II part. Of all pa-
tients, 40 (91 %) were evaluable for PSA response and 2
(5 %) for tumor response according to Response Evalu-
ation Criteria in Solid Tumors (RECIST). At the highest
dose level, 33 (86 %) patients were evaluable for immune
response analysis. Patient baseline characteristics are
depicted in Table 1. 36 patients had metastatic disease,
including 26 patients evaluable for immune response.
Treatment
During the phase I part, 12 patients received 256 (n = 3),
640 (n = 3), or 1280 μg (n = 6) mRNA. In the phase IIa
part, another 32 patients were enrolled to receive the
recommended dose (RD) of 1280 μg mRNA defined in
phase I. All 44 patients received at least 2 vaccinations,
31 patients (70 %) received complete treatment with 5
vaccinations (see Additional file 1: Table S5). 5 phase I
patients (11 % of total patient population) had a change
in dosing, including 3 patients with a dose escalation as
permitted by the protocol (1 at 256 μg, 2 at 640 μg).
Two patients of the highest dose group had dose reduc-
tions to 640 μg due to adverse events (AEs; urinary
retention, flank pain, and vomiting). Reasons for prema-
ture treatment discontinuation were disease progression
(n = 6), disease progression and possibly related serious
adverse events (grade 3 urinary retention, n = 1; grade 3
urinary retention with hydronephrosis, n = 1), unrelated
serious adverse events (n = 2), non-compliance (n = 1)
and withdrawal of consent (n = 1). Within the subgroup
of metastatic patients, 4 were treated in the phase I part
at 256 μg (n = 2) and 640 μg (n = 2) and 32 in the phase
IIa part at 1280 μg mRNA.
Results of phase I (dose escalation)
At the 2 lower dose levels, none of the patients experi-
enced a dose limiting toxicity (DLT). Of the first 3 pa-
tients enrolled to the highest dose level, 1 experienced a
DLT (Common Terminology Criteria for Adverse Events
[CTCAE] grade 3 urinary retention; possibly related) at
the week 5 visit. After week 5, this patient experienced 2
additional grade 3 DLTs, namely flank pain and vomiting.
Table 1 Baseline characteristics of the patient population
(N = 44)




Gleason score available, n (%) 39 (89)
≤7 15 (38)
>7 24 (62)
PSA level at baseline, ng/mL
Median 22.2
Range 0.2–746
Extent of disease, n (%)
Local relapse 6 (14)
Locoregional 1 (2)











Time since diagnosis, weeks
Mean 280.4
SD 228.15
Previous therapy, n (%)
Prostatectomy 23 (52)
Radiotherapy 28 (64)
Hormone ablation 44 (100)
ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen;
SD, standard deviation
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level. Two of these patients experienced DLTs of grade 3
(urinary retention) after the week 5 visit and were thus
not considered for the determination of the RD. Since
urinary retention is a common symptom of prostate can-
cer progression, the dose of 1280 μg was considered safe
and recommended for the phase IIa part of the trial by the
DSMB.
Safety results
Treatment-related AEs were experienced by 39 (89 %) pa-
tients, with a total of 282 related AEs reported. The most
frequent treatment-related side effects were injection siteerythema and injection site reaction in 27 (61 %) and 21
(48 %) patients, respectively. Fatigue (18 %), pyrexia (16 %),
chills (11 %), and influenza-like illness (11 %) were also
frequently reported (Table 2). A trend for a dose-
dependency of these AEs was not observed. In general,
AEs were manageable and resolved upon therapy.
The majority of related AEs were of mild to moderate
intensity. In 5 (11 %) patients, related AEs of CTCAE
grade 3 were reported, including urinary retention (n = 3),
vomiting (n = 1), disease progression (n = 1), decreased
neutrophil count (n = 1), flank pain (n = 1), confusional
state (n = 2), dyspareunia (n = 1), and hydronephrosis (n = 1).
The decreased neutrophil count (800/μl with a total leuco-
cyte count of 3900/μl) was measured only at the week 5
visit and neutrophils were again within normal range in
week 7. The patient was otherwise asymptomatic. Life-
threatening related AEs (CTCAE grade 4) were not ob-
served. One fatal AE was reported for a 68-year old
patient with bone metastases and a history of obstructive
pulmonary disease and right-sided heart insufficiency. He
was hospitalized due to disease progression and broncho-
pneumonia 1 month after having received the 4th vaccin-
ation. The event was considered possibly treatment
related since a relationship to vaccination could not be
excluded.
A total of 21 serious AEs (SAEs) were reported in 9
(20 %) patients, with the most frequent SAEs being urin-
ary retention and anemia in 3 (7 %) patients each and
hematuria in 2 (5 %) patients. SAEs considered possibly
treatment-related were reported in 2 (5 %) of patients
(grade 3 urinary retention and grade 3 urinary retention
with hydronephrosis) and occurred after the second vac-
cination. The events resolved after symptomatic and
antibiotic treatment. No adverse events indicating auto-
immune reactions were reported.
Immune responses
To define optimal methodology, cells from 3 patients at
1280 μg and 2 patients at 640 μg were re-stimulated
in vitro in the presence of vaccination antigens and cyto-
kines to increase the frequencies of vaccine-induced
antigen-specific cells before analysis. However, to gener-
ate reliable results that reflect the physiological response,
we decided to analyze the other immunological evalu-
able patients ex vivo, including 33 high dose patients.
In total, 38 of 44 patients were evaluable for immune
responses according to study protocol. Criteria to define
responders were adapted from CIMT/CIC criteria [29].
Quantitative analysis of ELISpot, ICS, and tetramer
staining assays revealed that CV9103 was able to induce
both CD4 and CD8 T cell responses. The percentage of
high-dose patients with increased frequencies of T cells
releasing cytokines in an antigen-specific manner after
vaccination was 27 % for CD8 cells and 42 % for CD4










Total N = 44 Total N = 44
N = 3 N = 3 N = 38
Grade 1/2 Grade ≥3 Grade 1/2 Grade ≥3 Grade 1/2 Grade ≥3 Grade 1/2 Grade ≥3 All Grades
Total patients with related AEs 2 (67) 1 (33) 2 (67) 1 (33) 30 (79) 3 (8) 34 (77) 5 (11) 39 (89)
General disorders and
administration site reactions
2 (67) 1 (33) 3 (100) 0 32 (84) 0 37 (84) 1 (2)*1 38 (86)
Injection site erythema 2 (67) 0 2 (67) 0 23 (61) 0 27 (61) 0 27 (61)
Injection site reaction 2 (67) 0 1 (33) 0 18 (47) 0 21 (48) 0 21 (48)
Fatigue 2 (67) 0 0 0 6 (16) 0 8 (18) 0 8 (18)
Pyrexia 0 0 1 (33) 0 6 (16) 0 7 (16) 0 7 (16)
Chills 1 (33) 0 0 0 4 (11) 0 5 (11) 0 5 (11)
Influenza-like symptoms 0 0 0 0 5 (13) 0 5 (11) 0 5 (11)
Musculoskeletal and connective
tissue disorders3
1 (33) 0 0 0 5 (13) 1 (3) 6 (14) 1 (2) *2 7 (16)
Nervous system disorders4 1 (33) 0 1 (33) 0 4 (11) 0 6 (14) 0 6 (14)
Renal and urinary disorders5 0 0 0 1 (33) 3 (8) 2 (5) 3 (7) 3 (7)*3 6 (14)
Skin and subcutaneous disorders6 0 0 0 0 6 (16) 0 6 (14) 0 6 (14)
Gastrointestinal disorders7 1 (33) 0 0 0 3 (8) 1 (3) 4 (9) 1 (2)*4 5 (11)
1 Adverse events (AEs) by system organ class (SOC) and/or preferred term (PT) that occurred in at least 10% of patients
2 Multiple occurrences of the same AE in one patient are counted once
3 Musculoskeletal and connective tissue disorders includes the following terms: arthralgia, muscle spasms, muscular weakness and pain events
4 Nervous system disorders includes the following terms: somnolence, tremor, disturbance in attention, dizziness, dysgeusia
5 Renal and urinary disorders includes the following terms: urinary retention, urinary tract obstruction, dysuria, hydronephrosis, micturition urgency, obstructive
uropathy and urinary incontinence
6 Skin and subcutaneous tissue disorders includes the following terms: erythema, pruritus
7 Gastrointestinal disorders include the following terms: diarrhea, constipation, abdominal pain, dry mouth, gingival bleeding, vomiting
*1disease progression; *2flank pain; *3urinary retention (n = 2); urinary retention and hydronephrosis (n = 1); *4vomiting
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specific cells against at least one antigen were increased
compared with baseline at least at one time point. 12 %
of patients showed both CD8 and CD4 responses, while
55 % of patients had either CD4 or CD8 responses as
assessed by ELISpot and ICS.
In 12 HLA-A2-positive patients at 1280 μg, antigen-
specific CD8 T cells were detected in 7/12 (58 %) of pa-
tients by tetramer staining (Fig. 1). Overall, in 25/33 (76
%) evaluable patients treated at 1280 μg a cellular im-
mune response could be detected.
Analysis of humoral responses to vaccine antigens was
limited in this study, because only PSA and PSCA were
available as full proteins eligible for ELISA, and amounts
of PSCA protein allowed for testing 23 patients at
1280 μg only. Although antibody levels were already de-
tectable at baseline in almost all patients hinting at pre-
existing humoral immune responses, 4 patients showed
an increase of anti-PSA antibodies over the course of
vaccination. No increase of anti-PSCA antibodies in
evaluated patients could be detected.
Of note, cellular CD4 and CD8 immune responses
against all 4 antigens of CV9103 were observed (Fig. 2),independent of their cellular localization (PSA: secreted
protein, PSCA: GPI-anchored protein, PSMA: type II
trans-membrane protein, STEAP: six trans-membrane
spanning protein, see Additional file 1: Table S1). 42 %
of immunologically responding patients responded to
only 1 antigen (single responders), whereas 31 % recog-
nized two, 19 % three and 8 % all four antigens, resulting
in 58 % multiple responders (patients responding against
more than 1 antigen; Fig. 3). As expected for ex vivo as-
says, the absolute frequency of antigen-specific T cells is
relatively low; notably, in the majority of responders, the
T cells increased more than 2-fold compared with base-
line (Fig. 4).
Within the observed range, immune responses after
vaccination with CV9103 were not age-dependent. At
the recommended dose, an overall response was de-
tected in 75 % of patients ≤65 years (n = 12), whereas in
patients above 65 years (n = 21), CV9103 vaccination
showed an overall immunogenicity in 81 % of patients
(Additional file 2: Figure S1). In addition, logistic regres-
sion analysis did not identify a significant correlation be-
tween age and immune responses (p = 0.88). These
































Fig. 1 Cellular immune responses to CV9103. Evaluation of antigen-
specific cellular immune responses as measured ex vivo by ELISpot,
ICS and tetramer staining. Shown is percentage of patients responding
against≥ one antigen at≥ one time point within evaluable patients
(n = 33). Percentages of responding patients are indicated for patients
eliciting a CD4 response, a CD8 response, both CD4 and CD8 responses
and either CD4 or CD8 responses. Tetramer binding was measured
only in HLA-A2+ patients (n = 14)
Fig. 2 Evaluation of antigen-specific cellular and humoral immune respons
antigen contained in the vaccine by CD4 response, CD8 response, both CD
responses were measured only in HLA-A2+ patients (n = 14), humoral respo
detected for PSA, 23 patients tested for anti PSCA antibodies showed no in
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mune responses after RNActive® vaccination [30].
At 256 μg, none of the 3 patients treated showed an im-
mune response to any of the included antigens. At 640 μg,
immune responses were observed in 2 patients, including
1 patient with a humoral response to PSA and 1 patient
with a cellular response to PSA, PSMA and STEAP after
in vitro re-stimulation. These patients were not included
in the overall analysis of immune responses.
To evaluate frequencies of lymphocyte subpopulations
and expression of activation and maturation markers, we
performed cell phenotyping including antibody panels
specific for B cells, T cells, NK cells and regulatory T
cells. A striking decrease or increase as compared to
baseline levels of any lymphocyte subset or maturation
or activation markers on those subsets was not observed.
However, the frequency of antigen-unspecific CD19+ B
cells was increased in 68 % of patients at two or three
time points after vaccination, with at least two-fold fre-
quencies compared with baseline in 14/31 patients (45 %)
(Additional file 2: Figure S2). For a summary of immune
responses see Additional file 1: Tables S4, S6, S7).
Clinical efficacy results
To assess a potential impact of CV9103 on the clinical
course of prostate carcinoma patients, PSA progression-
free survival (PSA-PFS; interval from the first vaccin-
ation to PSA progression according to Prostate Canceres per antigen. Percentage of patients (n = 33) responding against each
4 and CD8 responses and either CD4 or CD8 responses. Tetramer
nses were measured only against PSA and PSCA and could only be
crease over time
Fig. 3 Responses against multiple antigens. Frequency of patients
responding against multiple antigens within responding patients.
Percentages of positive patients are indicated for the number of
recognized tumor antigens and for multiple (≥2) recognized
antigens in total. The majority of immune-responding patients
exhibited responses against ≥2 different tumor antigens (PSA, PSCA,
PSMA and STEAP1)
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38 patients at 1280 μg CV9103. Median PSA PFS was
1.8 month [95 % CI: 1.4; 3.2], the 6 months PSA PFS
rate was 15.9 %.
One patient with lymph node metastases and a Gleason
score of 9 at diagnosis had a confirmed PSA response
with a maximum decline of PSA >80 % from baseline in
week 23 without any supplementary anti-cancer therapy
(Additional file 3 shows this case in detail). After an ini-
tial rise in week 7, a substantial decline of PSA level was
observed in this patient, which was confirmed another
4 weeks later (Baseline PSA: 3.96 μG/L; Week 7: 9.75 μG/L,
Week 23: 1,36 μG/L, confirmed one month later: 0,96 μG/Fig. 4 Antigen-specific T cells (frequency and number) at baseline and pos
on CD8+ population for tetramer staining (n = 17), percentage of positive c
staining (n = 26) and SFC/1×106 total PBMCs for IFN-γ ELISpot (n = 14). Resp
with baseline irrespective of the time pointL). No further PSA follow up values were available. The pa-
tient died 30 months after start of CV9103 treatment. Im-
munologically, this patient had a cellular immune response
to PSA with a 9-fold increase of PSA-specific CD4 T cells
detected by ICS in week 9. A positive humoral response
against PSA according to pre-defined criteria was not de-
tected in this patient due to high assay variation at baseline,
still levels of anti PSA IgG exceeded the baseline levels at
week 5.
In 2 patients, tumor assessment according to RECIST
was evaluable, but none of them showed an objective
response.
Median OS for all 44 patients was 29.3 months [95 %
CI: 21.2; n.a.] (Fig. 5a), in the subgroup of patients with
metastatic disease (n = 36), median OS was 31.4 months
[95 % CI: 21.2; n.a.] (Fig. 5b).
Correlation of immune response and survival data
To further assess the clinical impact of CV9103, the ef-
fect of immune responses on survival was analyzed. 33
patients were immunologically evaluable. Of these, 26
patients had metastatic disease, including 20 patients (77 %)
with cellular immune responses as analyzed by ex vivo
methods and 1 patient (within these 20 patients) showing
an additional humoral response. Correlation of current
survival data with observed immune responses after treat-
ment with CV9103 revealed a trend for longer survival
times in patients responding to the vaccine (Fig. 6a). The
HR for death of these patients compared with immuno-
logical non-responders was 0.3 [95 % CI: 0.08; 1.15] with a
p-value of 0.09 (Fig. 6a).
Furthermore, patients exhibiting an immunological re-
sponse to more than one antigen (multiple responders)
had longer survival times than non-responding patients
or patients responding to only one antigen (HR = 0.41,
[95 % CI: 0.17; 0.95], p = 0.017). Kaplan-Meier survivalitive time point. Values are given in percentage of positive cells gated
ells gated on CD4+ or CD8+ populations for intracellular cytokine (ICS)
onses are showing the maximum increase post-baseline compared
ab
Fig. 5 Kaplan-Meier plots of overall survival. Kaplan-Meier survival
estimates are presented for (a) All patients (n = 44): median OS was
29.3 months 95 % CI: [21.2; n.a]. (b) Patients with metastatic disease
(n = 36): median OS was 31.4 months 95 % CI: [21.2; n.a.]
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antigens of CV9103 (Fig. 6b).
Discussion
For men with metastatic CRPC, treatment options have
been limited in the past. In the recent years though, a
range of novel treatments, including several immuno-
therapy approaches, have been in development. Here, we
report the tolerability, safety and immunogenicity of a
novel immunotherapy for patients with advanced CRPC
using recently developed modified mRNA molecules as
a vaccine. CV9103, encoding the full length proteins
PSA, PSCA, PSMA and STEAP, was designed and tested
in a phase I/IIa clinical study. In phase I, 3 doses of
CV9103 were administered to patients to define a safe
dose for phase IIa. The highest dose of 1280 μg mRNA
was selected for the extension cohort.
CV9103 mRNA was well tolerated and showed a good
safety profile. The observed cases of urinary retention
and hydronephrosis reported in the present trial might
have been related to progression of the underlyingprostate cancer, with tumor masses impacting the ur-
ethra or the ureters. However, a vaccine-induced im-
mune response may stimulate infiltration of lymphocytes
into the tumor, which could result in an increased tumor
volume representing a pseudo-progression, as reported
for other immunotherapies [31]. Hence, a potential con-
tribution of CV9103 to these events cannot be excluded,
and might have been associated with the desired im-
mune reaction against the tumor. In future trials, tumor
biopsies taken at the time of tumor volume increase
may help to clarify the etiology of such events.
The observed injection site erythema, injection site reac-
tions and influenza-like symptoms were mild to moderate
and have been observed in previous clinical trials with
cancer vaccines [5], including mRNA vaccines [10, 32, 33].
Serious AEs of autoimmunity have been reported in re-
cent trials with the checkpoint inhibitors ipilimumab
(anti-CTLA-4 monoclonal antibody) and nivolimumab
(anti-PD1 monoclonal antibody) [34–36], and also rarely
for other cancer vaccines. Importantly, we did not observe
any clinical AEs indicative of autoimmune reactions upon
administration of CV9103.
In addition to a good tolerability and safety profile,
CV9103 was shown to be immunogenic in the present
study. To induce an effective immune attack against can-
cer antigens it is necessary to overcome immunological
tolerance [37] by combining immunogenic antigens with a
strong adjuvant. The new format RNActive® carries both
the antigen and the necessary adjuvant effect within one
vaccine. Accordingly, the present data on immunogenicity
of CV9103 showed that immune responses could be elic-
ited against all encoded antigens, independent of their
cellular localization (Additional file 1: Table S1). In order
to measure physiological numbers of vaccine-induced
antigen-specific cells, PBMCs were not re-stimulated
in vitro with the vaccination antigens prior to conducting
the assays. A ≥2-fold increase of cytokine releasing cells
after antigenic stimulation as measured by ex vivo ELISpot
or ICS was observed in 19/33 (58 %) of patients at the rec-
ommended dose. This antigen-specific immunity con-
sisted of both CD4 and CD8 T cells. 7 out of 12 HLA-A2
positive patients had increased frequencies of MHC-
multimer-binding cells after vaccination. Hence, a cellular
immune response was observed in 76 % (25/33) of the pa-
tients, in some as early as after the second immunization.
The observed immune responses were not consistent over
time in the majority of patients, a similar kinetics has also
been seen in other cancer vaccine trials[38]. In the de-
scribed study, possible reasons for this may be the low
number of sampling timepoints, the timing of blood sam-
pling in relation to vaccination timepoints, or the detec-
tion limit for immunological ex vivo assays.
It cannot be excluded that the results of the present
study underestimate the true level of T cell responses
Fig. 6 Kaplan-Meier plots of overall survival by immunological responses. (a) Kaplan-Meier survival curves of metastatic patients evaluable for
immune responses (n = 26), including immunological responders (n = 20) and non-responders (n = 6). The Hazard Ratio of survival for responders
versus non-responders was 0.30, [95 % CI: 0.08; 1.15], p = 0.09. (b) Kaplan-Meier survival curves of metastatic patients evaluable for immune
responses (n = 26), evaluated according to the number of CV9103 antigens the patients responded to. The Hazard Ratio was 0.41, [95 % CI: 0.17;
0.95], and p = 0.017
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epitopes derived from the full-length mRNA of CV9103
are HLA-genotype-dependent and hence may vary in be-
tween patients. Analyses of T cell responses were con-
ducted using selected peptides of the 4 antigens, either
previously described or predicted, which may not repre-
sent all epitopes generated in every patient. In addition,
analyses were performed ex vivo to obtain physiologic-
ally realistic results regarding frequency of induced im-
mune responses. After initial testing in few patients, an
in vitro re-stimulation was not performed to preventartificial generation of antigen-specific T cells in cell cul-
ture. Regarding the limits of detection of the applied as-
says, this may render an explanation for inconsistent
responses in different assays.
The assessment of humoral immune responses was re-
stricted to PSA and PSCA, since no proteins suitable for
ELISA were available for the other vaccination antigens.
An increase of PSA-specific antibodies could be detected
in 4/33 patients, but no increase of anti-PSCA anti-
bodies was observed. To our knowledge, induction of
PSCA-specific antibodies has not been investigated so
Kübler et al. Journal for ImmunoTherapy of Cancer  (2015) 3:26 Page 9 of 14far, although PSCA has been used as a target for immuno-
therapy of prostate cancer using various vectors [39].
Of note, 58 % (15/26) of responding patients and 45 %
(15/33) of all evaluable patients at the highest dose level
showed responses to multiple vaccination antigens (31 %
against two, 19 % against three, 8 % against all four anti-
gens). Similar overall immunological results were ob-
tained in previous clinical trials with non-RNActive®
mRNA vaccines [10, 32, 33, 40]. Recent data published
on a peptide-based vaccination approach in renal cell
carcinoma suggested that multi-antigen responses may
be related to improved survival [38]. A trend towards
longer survival times was also observed in patients
responding to more than one antigen of CV9103.
The frequency of regulatory T cells was assessed using
an epigenetic assay that is based on a PCR-assay measur-
ing the methylation level of the FoxP3 gene and is de-
scribed to detect regulatory T cells from peripheral
blood more reliably than classical CD4+CD25hiFoxP3+
intracellular staining [41]. During the course of vaccin-
ation, no change in the frequency of regulatory T cells
could be detected in any of the patients. This result is in
line with pre-clinical experiments, where no de- or in-
crease of CD4+FoxP3hi regulatory T cells was detected,
while antigen specific CD4 and CD8 T cells as well as
tumor responses were measured. Also, no relation be-
tween frequency of regulatory T cells and overall survival
time or regulatory T cells and immune response could
be detected (Additional file 2: Figure S3).
Clinical efficacy of CV9103 was assessed mainly by
progression of PSA, radiographic PFS was not assessed
in this trial. Only two patients were evaluable for RECIST
response evaluation since regular CT scans were not re-
quested per protocol. Besides the small sample size and
lack of a control group, the fact that no systematic tumor
imaging was performed limits our ability to conclude on
clinical efficacy. A median time to PSA-PFS of 1.8 months
and an objective PSA response in only one patient upon
therapy with CV9103 are typical results for cancer vac-
cines known to induce clinical response patterns that dif-
fer from those of cytotoxic agents and many targeted
therapies. Cancer vaccines may e.g. induce delayed re-
sponses not seen in the first few months of therapy, or ini-
tiate a dynamic immune response that in spite of no
observable tumor shrinkage will ultimately slow tumor
growth rate [42]. In clinical trials with the prostate cancer
vaccines Sipuleucel-T and ProstVac-VF, no significant
effect on the time to objective disease progression was ob-
served, although overall and 3-year survival was signifi-
cantly increased [4, 5]. Importantly, PSA responses were
also very rarely observed in these trials, indicating that
PSA is no suitable surrogate to predict response to a can-
cer vaccine. Possibly, the effect of subsequent therapies
may be increased by induced immune responses, resultingin a combination that is more effective than conventional
treatments alone and may explain the prolonged survival
despite lack of PFS prolongation. Indeed, patients that
progressed on Sipuleucel-T and received docetaxel as sub-
sequent therapy had much better overall survival than pa-
tients on placebo followed by docetaxel [43, 44]. In the
subgroup of 36 patients with metastatic CRPC treated
with CV9103, the Kaplan-Meier estimate of median OS
was 31.4 months [95 % CI: 21.2; n.a.]. A non-significant
correlation of survival time and immune responses was
observed (HR = 0.30, p = 0.09). Outcome further improved
in patients with responses to more than one antigen of
CV9103 (HR = 0.41, p = 0,017). The analysis of immuno-
logical response as a predictor for survival was restricted
to simple univariate models treating the immunological
response as baseline variable. Due to low sample size the
presented analysis is regarded to be an adequate presenta-
tion of the underlying data. A correlation of immune re-
sponses against more than one antigen and improved
survival time has also been shown by others [38] and does
not necessarily imply a therapeutic effect of vaccination
since the ability to mount an immune responses after vac-
cination might be a surrogate of an improved prognosis.
Thus the investigation of the vaccine in a controlled
clinical trial seems justified. Based on these results, a
randomized, placebo-controlled phase IIb study in CRPC
started to enroll patients in 2012 using CV9104, an ad-
vanced vaccine variant of CV9103 (www.clinicaltrials.
gov, NCT01817738). The primary endpoint of this trial
is OS with PFS according to the criteria of the PCa
working group as secondary endpoint. Further secondary
endpoints will clarify the impact of immune response on
overall survival and seek to determine biomarkers asso-
ciated with improved survival. 197 patients with meta-
static asymptomatic or minimally symptomatic CRPC
have been randomized, a population expected to benefit
from vaccinations as shown in the past. By using a large
sample size and a placebo group, the trial will allow for
evaluation of the therapeutic potential of mRNA vaccin-
ation against multiple antigens in PCa.
Interestingly, combinations with other immuno-
modulatory agents might contribute to breaking tumor
tolerance [45] and thus further improve novel, immu-
netherapeutical approaches such as treatment with self-
adjuvanted mRNA molecules. Pre-clinical experiments in
mouse models have indeed shown a synergistic effect of
combination regimens including mRNA vaccination with
CTLA-4 blockade [13] or radiotherapy (unpublished data),
suggesting that the investigation of these combinations in
clinical trials might be promising.
Conclusions
In conclusion, in the present study, vaccination by intra-
dermal injection of CV9103, a self-adjuvanted, two-
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tumor associated antigens of PCa, was well tolerated and
induced immune responses that may result in prolonged
survival in patients with CRPC. Overall, this trial sug-
gests that the RNActive® vaccination technology consti-
tutes an effective and nimble platform to generate
immune responses against virtually any protein antigen.
Methods
RNActive® technology
CureVac GmbH proprietary technology generated mRNA
molecules with increased stability and translatability
(patents EP1392341, EP1857122, and application WO20
12019780A1). The RNActive® vaccines consisted of a mix-
ture of free modified mRNA (component 1) and mRNA
complexed with protamine at a weight ratio of 2:1 (com-
ponent 2). First, mRNA was complexed by the addition of
protamine-Ringer lactate solution and, after stable com-
plexation, free mRNA was added [14]. All mRNA vaccines
used in the present study were produced in accordance
with current Good Manufacturing Practice guidelines.
Patients
Study participants were at least 18 years of age with pro-
gressive metastatic or non-metastatic CRPC, defined by
a rise in PSA at three consecutive time points (PSA rise
over nadir, separated by >1 week, PCWG2 criteria) and/
or RECIST-based or bone-scan based progression of eva-
luable lesions while the patient has a castrated level of
testosterone (achieved either by orchiectomy or GNRH
analogue with or without anti-androgen). Anti-androgens
had to be discontinued at least 4 weeks prior to enroll-
ment to exclude a withdrawal response. Patients had to
have a life expectancy of >12 months as assessed by the
investigator. Previous chemotherapy was not allowed and
patients with a history of autoimmune disorders were ex-
cluded. Eligibility criteria included an Eastern Cooperative
Oncology Group (ECOG) performance status of ≤1 and
adequate total bilirubin and renal, hepatic, cardiac, and
bone marrow function. Patients requiring bisphospho-
nates at the time of registration into the trial were eligible
as long as therapy was initiated at least 28 days prior to
first study treatment administration and continued at a
constant level during the study period (for a complete list
of eligibility criteria see Additional file 1: Table S2).
Study design and treatment
The present study was a prospective, multicenter, open-
label, uncontrolled phase I/IIa trial performed at 12
study sites in Germany and Italy (for list of involved
ethic commitees see Additional file 4: Table S8). The
starting dose of 256 μg mRNA was selected based on
data of single and repeat dose toxicity studies in mice. In
these toxicity studies, a No Observed Adverse EffectLevel (NOAEL) was not reached up to an mRNA dose
of 256 μg per application. Dose escalation of CV9103
(phase I) was based on a Fibonacci 3 + 3 design with
dose-limiting toxicity (DLT) defined as Common Ter-
minology Criteria of Adverse Events (CTCAE) grade 3/4
related neutropenia with fever and/or infection, CTCAE
grade 3/4 related non-hematological toxicity, or dosing
delay >2 weeks due to toxicity. Primary objective of the
phase I part was determination of the recommended
dose (RD) for phase II, defined as the highest dose level
in which DLT was observed in ≤1 of 6 evaluable patients
before the Week 5 visit. In the extension cohort at RD
(phase IIa), the primary objective was assessment of
safety. Secondary objectives were evaluation of induction
of immune responses and anti-tumor activity. Immuno-
logical efficacy endpoints were the assessment of induc-
tion of antigen-specific cellular and humoral immune
responses and the evaluation of levels of regulatory T
cells during the course of treatment. Clinical efficacy
endpoints were PSA-PFS, objective response according
to RECIST and overall survival. Radiographic imaging
was to be performed at the discretion of the investigator.
Immuno-suppressants, systemic steroids as well as an-
ticancer agents or investigational agents were prohibited
during the course of the study treatment. Patients ex-
periencing pain or fever following vaccination could be
treated with non-steroidal anti-inflammatory drugs such
as ibuprofen as required.
CV9103 consists of RNActive®-based mRNA compo-
nents encoding the antigens PSA, PSMA, PSCA, and
STEAP1 (Additional file 1: Table S1). At every vaccin-
ation, 64 μg, 160 μg, or 320 μg mRNA of each antigen
was administered for a total dose of 256 μg, 640 μg, or
1280 μg mRNA, respectively. Each CV9103 component
was administered as 2 intradermal injections of 200 μl
each (total: 8 injections per vaccination), one into the
thigh and one into the upper arm of the same body half.
Injection sites of each antigen were rotated clockwise at
different vaccination days. Patients were vaccinated on
weeks 1, 3, 7, 15, and 23. After the last vaccination further
anti-tumor therapy was at the discretion of the investiga-
tor. Data cutoff for survival analysis was December 2012.
Assessment of safety
Adverse events (AEs) were recorded at each visit and
graded according to the National Cancer Institute (NCI)
Common Terminology Criteria of Adverse Events (CTCAE)
version 3.0 from the first dose until 28 days after the last
dose of CV9103. Relatedness to vaccination was assessed
by the investigators and events that were considered at
least possibly related were counted as related in the final
analysis. During dose-escalation, DLT occurring prior to
Week-5 visit was assessed. The escalation to higher dose
levels and the selection of the RD took place under
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sisting of investigators, the sponsor’s medical representa-
tive, the CROs medical monitor and an independent
expert. Routine hematological and biochemical tests were
performed at all visits and autoimmunity assessments
(rheumatoid factor, antinuclear antibody titer, TSH, anti-
bodies against thyroglobulin and smooth muscle anti-
bodies) were assessed at baseline, week 5, 15, and at the
end of the study.
Assessment of immunogenicity
Immune responses were evaluated in all patients who re-
ceived at least 3 vaccinations. The rate of vaccine
antigen-specific humoral and cellular immune responses
as well as regulatory T cell frequency was determined at
weeks 5, 9, and 17 (2 weeks after 2nd, 3rd and 4th vac-
cination) and compared to baseline. Humoral immune
response was assessed by IgG- or IgM-ELISA. Cellular
immune response (antigen-specific T lymphocytes) was
assessed by ELISpot, ICS, and tetramer staining (see
below). Phenotyping was performed to identify various
lymphocyte subsets and maturation/activation markers
on NK, B and T cell subsets. For analysis, samples of pa-
tients were thawed and all time points from each patient
were analyzed simultaneously. All laboratory procedures
were performed according to approved, validated SOPs
and in the style of CIC/CIMT protocols [29]. ELISpot,
ICS and Tetramer staining were validated using a model
antigen (CMV) for inter- and intra assay precision, spe-
cificity, robustness and linearity (ELISpot only) accord-
ing to ICH guidelines. A patient was considered to be a
responder if they responded in at least one assay against
at least one antigen at least one time point.
Preparation of peripheral blood mononuclear cells (PBMCs)
PBMC preparation from blood samples was performed
using a study specific PBMC preparation kit (Interlab
GmbH, Munich, Germany) containing all necessary ma-
terials and buffers. Briefly, blood was transferred from
the heparin tube to the Leucosep tube (Greiner Bio-
One, Germany) and centrifuged. PBMCs were harvested
from the interphase and washed twice. Viability was
assessed by Trypan-Blue staining, yield and red blood
cell contamination was assessed by Turk’s solution for
cell counting. Cells were frozen till analysis in DMSO-
free freezing medium (Cryo-SFM, Promocell).
Enzyme-linked immunosorbent assay (ELISA)
The levels of anti-PSA and anti-PSCA antibodies (IgG
and IgM) were evaluated by ELISA using four serial di-
lutions. The wells of a maxisorb plate were coated with
purified human PSA protein (Scipac), or recombinant
PSCA protein (CCS, Hamburg, Germany). After block-
ing, patient plasma was added. A secondary antibody(anti-IgG-HRP and anti-IgM-HRP, Jackson Immuno-
Research) was used for detection by the ELISA reader
(Tecan Sunrise, Biotek Synergy HT) (absorbance at
450 nm). Serum of healthy volunteers was used as negative
control, antigen-specific monoclonal mouse-anti-human
antibodies were used as control. Antibody responses were
considered positive if samples were ≥ baseline value (Week
1) plus 2 times standard deviation of baseline titer (S.D.).Epitope selection
As target in cellular cytokine secretion assays, patient
specific peptide cocktails were used. Predicted peptide
pools for each antigen consisted of epitopes for the fol-
lowing HLA-types: Class I: HLA-A1, HLA-A2, HLA-A3,
HLA-A24, HLA-B7, HLA-B8, HLA-B35, HLA-B44 and
Class II: HLA-DRB1-01, HLA-DRB1-03, HLA-DRB1-04,
HLA-DRB1-07, HLA-DRB1-011, HLA-DRB1-015, and
were chosen according to the patient’s haplotype.
Preferably, known immunogenic epitopes were used.
For antigens or haplotypes with no known epitopes, a
binding prediction with SYFPEITHI (http://www.syf
peithi.de), Rankmap, Bimas (http://www-bimas.cit.nih.
gov/molbio/hla_bind/) and Net MHC (www.cbs.dtu.dk/
services/NetMHC/) was performed. Altogether, 2–3 pep-
tides per allele (2–9 per antigen) were used (Additional
file 1: Table S3).Enzyme-linked immunosorbent spot assay (ELISpot)
According to CIMT/CVC protocol recommendations
[29, 46–48] PBMCs were rested overnight at 37 °C and 5 %
CO2 in cell culture medium and seeded at 300.000 cells/
well in 200 μL serum-free culture medium in 96-well
PVDF plates pre-coated with anti-IFN-γ antibody. After
incubation for 24 hours, cells were stimulated with
serum-free X-Vivo 15 medium (Lonza) containing indi-
vidual peptide pools as described above. PBMCs cultured
in the presence of Staphylococcus enterotoxin B (SEB)
and CMV/Eppstein-Barr/Flu (CEF) peptide mix (JPT)
were used as control for cell reactivity. The number of
IFN-γ-producing cells was evaluated using an automated
ELISpot reader (CTL ImmunoSpot Analyzer, Cellular
technology limited). Antigen-specific T cell responses
were considered positive if all of the following five criteria
were fulfilled: samples were ≥2-fold background value
(negative control peptide) and ≥2-fold baseline value
(Week 1), displayed a minimum of 5 spots and could be
measured as triplicate values (at least duplicates in case of
limited cell numbers), and were without overlapping error
bars (adapted from: response definition criteria for ELI-
Spot assays, Association for Cancer Immunotherapy
(CIMT)). Representative data for ELISpot and other assays
used to monitor immune responses is shown in Additional
file 2 (Figure S4).
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Two million PBMCs were incubated at 37 °C with anti-
genic peptides pools of PSA, PSMA, PSCA, and STEAP1
in the presence of anti-CD28 antibody for 1–1.5 h and,
after addition of Brefeldin A and Monensin, for add-
itional 6-8 h. For flow-cytometric analysis, the cells were
stained with a viability dye to exclude dead cells, followed
by staining of CD4, CD8 and CD56. After permeabiliza-
tion, staining for IFN-γ and TNF-α was performed. The
proportion of cytokine-producing cells within the CD8+
and CD4+ T cell populations was calculated. Antigen-
specific T cell responses were considered positive, if sam-
ples were ≥2-fold background (negative control peptide)
and ≥2-fold baseline value (Week 1) and had at least
0.02 % positive cells.
Tetramer staining
Two million PBMCs of HLA-A2-positive patients were
stained with anti-CD4 and anti-CD8 antibodies and
incubated with Streptavidin-PE- or Streptavidin-APC-
conjugated tetramers of PSA, PSMA, PSCA, and STEAP1.
Two tetramers were used for each antigen (monomers
provided by Immatics Biotechnologies GmbH, Tuebingen,
Germany). A tetramer containing an HLA-A2 peptide of
human immunodeficiency virus (HIV) was used as a con-
trol. The proportion of tetramer-positive cells within the
CD8+ T cell population was calculated. Antigen-specific T
cell responses were considered positive if samples were ≥
mean negative control plus 3 times S.D. and ≥2-fold base-
line value (Week 1) and had at least 0.02 % positive cells.
Phenotyping
After thawing, 200.000 PBMCs were directly stained for B
cell (CD19, CD25, CD69, CD80, CD86), T cell (CD3, CD4,
CCR7, CCR5, CD25, CD69), and NK-cell markers (CD16,
CD25, CD56, CD69) and analyzed by flow cytometry.
Regulatory T cell measurement
Frequency of regulatory T cells was measured using a
quantitative DNA methylation analysis of FOXP3. 1×106
cells were frozen in 400 μl PBS and analyzed by Epiontis,
Berlin (http://www.epiontis.com).
Assessment of efficacy
Serum PSA levels were to be determined at baseline, at
weeks 7, 15, and 23, at end of treatment, and every
3 months during follow-up until week 52 (follow-up as-
sessments to be performed at local laboratories). Values
obtained after start of subsequent therapies with poten-
tial effects on PSA levels (new anti-hormonal agents,
corticosteroids, and/or chemotherapy) were not included
in the assessment of PSA response. Patients who re-
ceived vaccinations up to week 15 and had PSA assess-
ments at least at baseline, week 7 and week 15 wereevaluable for PSA response. PSA response and progres-
sion were assessed according to the PCWG2 criteria [31].
Radiological disease assessments were to be performed
according to standard practice of the treatment center.
Tumor response was assessed according to the Response
Evaluation Criteria in Solid Tumors (RECIST) version
1.0 [49]. Patients with measurable disease according to
RECIST who underwent a disease assessment within
1 month prior to treatment initiation and at least once
during treatment were evaluable for RECIST response.
All patients were followed-up for survival for 3 years
from start of the study. The frequency of assessment
was every 3 months during the first year and every
6 months for 2 years after the week 52 visit.
Statistical analysis
The sample size was chosen primarily on clinical and
safety considerations, formal power calculations were not
performed. The maximum number of enrolled patients
was dependent on the number of DLTs and patients with
early discontinuation of treatment. Dose escalation was
based on a Fibonacci 3 + 3 design. The statistical analysis
was descriptive. Means, medians, standard deviations, and
ranges were provided for continuous outcomes while fre-
quencies and percentages were reported for categorical
data. Overall survival was estimated according to the
Kaplan-Meier method. The relationships of explanatory
variables to overall survival were analyzed by univariate
Cox models using stratified by HLA-2+ type (due to add-
itional Tetramer analysis in HLA-A2+ patients) Likeli-
hood Ratio tests. For paired survival data (comparison
with predicted survival) the sign-rank test was used. Over-
all survival was defined as the interval from the date of
first vaccination to the date of death.
A retrospective analysis to evaluate the correlation be-
tween survival and induction of specific immune responses
was performed by applying a landmark analysis at 17 weeks
for the subgroup of 26 patients with metastatic disease
who were evaluable for immune response assessment.
All analyses were carried out using Stata 13. All pre-
sented p-values are two-sided. The study was conducted
in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines. The protocol was ap-
proved by the ethics committees of participating study
sites. Informed consent was obtained from all patients
prior to any study-related procedures.
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patients. Response against antigen, type of detected response, time of
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responding to two or more antigens.
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independent of age. Figure S2. CD19+ B cell levels showing anincrease
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phosphatase; PCa: Prostate cancer; PCWG2: Prostate cancer working group 2;
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